Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases

Table 2 Binary logistic regression models for clinically significant portal hypertension (CSPH) using dichotomized and continuous variables for serum CYFRA21-1 in Patients with portal hypertension due to ACLD (cohort ii)

	Serum CYFRA21-1, dichotomized ≥ 3.90 ng/mL		Serum CYFRA21-1, per ng/mL increase
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
Unadjusted	5.87 [2.95–11.68]	< 0.001	1.73 [1.40–2.14]	< 0.001
Adjusted for age and sex	6.19 [3.09–12.39]	< 0.001	1.77 [1.42–2.20]	< 0.001
Adjusted for etiology	5.25 [2.58–10.70]	< 0.001	1.73 [1.38–2.18]	< 0.001
Adjusted for age, sex, and etiology	5.47 [2.65–11.29]	< 0.001	1.79 [1.41–2.28]	< 0.001
Adjusted for platelet count	6.74 [3.19–14.22]	< 0.001	1.75 [1.40–2.18]	< 0.001
Adjusted for MELD score	4.07 [1.99–8.33]	< 0.001	1.53 [1.23–1.90]	< 0.001

CSPH was defined as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg. CYFRA21-1 was dichotomized using a cut-off determined by the maximum Youden index for the presence of CSPH. Abbreviations: CYFRA21-1 fragments of keratin 19, MELD model for end-stage liver disease

ISSN: 1741-7015